Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | STS | P08842 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397500 | 1.00 | CNR1 (0.68) | CNR1ALDH1A1TRPV1CNR2STS | |
| SCHEMBL28820388 | 0.98 | ALDH1A1 (0.68) | CNR1ALDH1A1TRPV1CNR2STS | |
| SCHEMBL17009241 | 0.95 | ALDH1A1 (0.68) | CNR1ALDH1A1TRPV1CNR2NPC1 | |
| SCHEMBL4901981 | 0.91 | MEN1 (0.63) | CNR1ALDH1A1TRPV1CNR2NPC1 | |
| SCHEMBL27892101 | 0.88 | ALDH1A1 (0.71) | CNR1ALDH1A1TRPV1CNR2EPHX2 | |
| SCHEMBL12215285 | 0.88 | CNR1 (0.85) | CNR1ALDH1A1CNR2STSEPHX2 | |
| SCHEMBL14060748 | 0.87 | CNR1 (0.67) | CNR1ALDH1A1TRPV1CNR2STS | |
| SCHEMBL16762031 | 0.87 | CNR1 (0.82) | CNR1ALDH1A1CNR2STSEPHX2 | |
| SCHEMBL27909118 | 0.87 | ALDH1A1 (0.72) | CNR1ALDH1A1TRPV1CNR2NPC1 | |
| SCHEMBL933945 | 0.85 | CNR1 (0.76) | CNR1ALDH1A1TRPV1CNR2STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372253-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023215314-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | 7 HILLS PHARMA INC. | 2021-05-20 | — | — | US | disclosed |
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | 7 HILLS INTERESTS LLC (US) | 2020-02-20 | — | — | US | disclosed |
| EP-3164127-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS, LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016003980-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | VCAM1, ITGB1, ITGA1 | CNR1 4340/4885ALDH1A1 613/4885TRPV1 2811/4885 |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | ITGB7, ITGA1, ITGAL | CNR1 1194/4885ALDH1A1 760/4885TRPV1 1347/4885 |
| US-20230372253-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | ITGAM, ITGA2, ADGRF1 | CNR1 737/4885ALDH1A1 2762/4885TRPV1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.